Abstract : Cancer-related pain remains one of the most distressing symptoms for oncology patients, and despite pharmacologic advances, a large proportion experience suboptimal relief or intolerable side effects from opioids and NSAIDs. Integrating evidence-based Ayurvedic formulations with standard care may offer a safer, multimodal approach to pain and symptom control. This paper proposes a scientific and regulatory framework for integrating selected Ayurvedic products in oncology pain and palliative medicine within evidence-based and ethical boundaries. A multidisciplinary clinical integration model was developed aligning with National Medical Commission, AYUSH, and Drugs and Cosmetics Act standards. Ayurvedic products were selected based on published data, pharmacologic mechanisms, and Good Manufacturing Practice compliance. Specific botanicals—Boswellia serrata, Curcuma longa, Withania somnifera, and Cannabis sativa leaf extract—demonstrated analgesic, anti-inflammatory, adaptogenic, and neuroprotective properties. Standardized Cannabis leaf tincture, rich in THC and CBD, acted via CB1 and CB2 receptors to modulate nociceptive signaling and reduce opioid load. Curcumin showed COX-2 inhibition, neuroprotective effects, and tumor-modulating activity, while hemp seed oil provided nutritional and anti-inflammatory support. Integrative oncology using standardized Ayurvedic formulations may complement conventional pain management, improving quality of life, reducing opioid dependence, and addressing fatigue, cachexia, and neuropathic pain. Proper regulatory compliance, patient monitoring, and multidisciplinary collaboration are essential for safe clinical application. Further clinical trials are warranted to validate efficacy and develop standardized integrative protocols for cancer pain and palliative care in India and globally.